AbbVie Beats Q2 Expectations, Raises Full-Year Guidance on Immunology Strength
The pharmaceutical giant reported adjusted EPS of $3.65 and revenue of nearly $17 billion, driven by double-digit growth in Skyrizi, Rinvoq, and neuroscience products.
Strong Quarter Prompts Guidance Raise
AbbVie Inc. reported second-quarter results that surpassed expectations, prompting the company to raise its full-year revenue guidance for the second time this year. The pharmaceutical giant posted adjusted earnings per share of $3.65, exceeding the guidance midpoint by $0.06, while total net revenues reached nearly $17 billion, beating expectations by $300 million and reflecting sales growth of 10.2% (earnings call, 2026-07-31).
"Based on this momentum, we are raising our full year revenue guidance by $300 million and have now raised total revenue by $600 million since the start of the year," said CEO Rob Michael during the earnings call (earnings call, 2026-07-31).
Immunology Portfolio Powers Growth
The immunology segment delivered revenues of nearly $8.8 billion, representing operational sales growth of 14.6%. Skyrizi led the charge with total sales of $5.5 billion, up 24% on an operational basis. Executive Vice President Jeff Stewart highlighted the drug's dominant market position, noting it captures new and switching patients "at a rate which is impressively 4x higher than any other biologic or oral treatment in the U.S." and has achieved market share leadership in more than 30 countries (earnings call, 2026-07-31).
Rinvoq also exceeded expectations with global sales surpassing $2.5 billion, up 23.7% operationally. The company expressed particular enthusiasm about growth potential in dermatology, with vitiligo and alopecia areata now approved in Europe and U.S. approval decisions anticipated "over the next few quarters." AbbVie now expects combined peak sales for these two indications alone to "approach $2 billion, which is meaningfully above our prior expectations" (earnings call, 2026-07-31).
Humira, facing biosimilar competition, posted global sales of $756 million, down 36.1% operationally but in line with company expectations.
Neuroscience Momentum Continues
The neuroscience portfolio delivered revenues exceeding $3.2 billion, up approximately 20% operationally. Vraylar sales reached nearly $1.1 billion, up about 19%, while the migraine portfolio—including Botox Therapeutic, Ubrelvy, and Qulipta—showed double-digit growth across all products.
In Parkinson's disease, VYALEV posted sales of $256 million, up more than 27% sequentially and "well on track to achieve blockbuster sales this year." The company anticipates U.S. approval and launch of tavapadon in the third quarter, with collective Parkinson's peak sales expected to exceed $5 billion (earnings call, 2026-07-31).
Pipeline Expansion Through Acquisition
AbbVie announced plans to acquire Apogee Therapeutics, adding "multiple differentiated assets in dermatology, respiratory and other related inflammatory diseases." Chief Scientific Officer Roopal Thakkar described the portfolio as "highly complementary to our immunology strategy" (earnings call, 2026-07-31).
The company emphasized it maintains "ample financial capacity for more business development" and remains focused on early and late-stage opportunities across core disease areas.
Other Segments Show Mixed Results
Oncology revenues totaled more than $1.6 billion, down 2.4% operationally, as double-digit growth from newer products partially offset a 29.4% decline in IMBRUVICA sales due to IRA pricing and competitive pressure. Aesthetics posted nearly $1.3 billion in sales, down 0.9% operationally, with Botox Cosmetic up 3.4% but Juvederm declining 6.6% amid dermal filler market headwinds.
This article was generated by MarginX from the earnings call on 2026-07-31. It is not investment advice.